Methods and systems to determine the lung clearance index (LCI) or other indices of ventilation inhomogeneity of lungs of a paediatric subject are provided. Inert tracer gas is washed-in and the wash-out is conducted by inhaling atmospheric air from the surroundings and exhaling to a confined space until the end-tidal tracer gas concentration has fallen below a predetermined fraction of the starting concentration. The LCI is calculated as the ratio between the cumulative expired volume (V.sub.CE) required to clear the inert tracer gas concentration from the lungs below a predetermined fraction of the starting concentration and the functional residual capacity (FRC) determined by dividing the net volume of inert tracer gas exhaled with the difference in end-tidal fractional concentration of the inert tracer gas at the start and end of the wash-out period; where V.sub.CE is determined by measuring the total volume in the collection bag after completed wash-out period.

Methods and systems to determine the lung clearance index (LCI) or other indices of ventilation inhomogeneity of lungs of a paediatric subject are provided. Inert tracer gas is washed-in and the wash-out is conducted by inhaling atmospheric air from the surroundings and exhaling to a confined space until the end-tidal tracer gas concentration has fallen below a predetermined fraction of the starting concentration. The LCI is calculated as the ratio between the cumulative expired volume (V.sub.CE) required to clear the inert tracer gas concentration from the lungs below a predetermined fraction of the starting concentration and the functional residual capacity (FRC) determined by dividing the net volume of inert tracer gas exhaled with the difference in end-tidal fractional concentration of the inert tracer gas at the start and end of the wash-out period; where V.sub.CE is determined by measuring the total volume in the collection bag after completed wash-out period.

An apparatus and method for collecting a breath sample are provided. The apparatus has a breath input interface configured to receive exhaled breath, a container connected to the breath input interface for receiving at least some of the exhaled breath, the container having a cavity with a volume that is controllable, and at least one controller configured to control the volume of the cavity to increase at a volume increase rate that is at most equal to a flow rate of the exhaled breath received by the breath input interface.

An apparatus and method for collecting a breath sample are provided. The apparatus has a breath input interface configured to receive exhaled breath, a container connected to the breath input interface for receiving at least some of the exhaled breath, the container having a cavity with a volume that is controllable, and at least one controller configured to control the volume of the cavity to increase at a volume increase rate that is at most equal to a flow rate of the exhaled breath received by the breath input interface.

An apparatus and method for collecting a breath sample are provided. The apparatus has a breath input interface configured to receive exhaled breath, a first conduit system connected to the breath input interface, at least one breath sample storage device connected to the breath input interface via a breath intake conduit of the first conduit system extending between the breath input interface and the breath collection system, the at least one breath sample storage device being configured to capture at least some of the breath, and at least one metering device for measuring at least one characteristic, the at least one metering device being positioned along an exhaust conduit of the first conduit system that branches from the breath intake conduit.

The present invention is related to the field of bio/chemical sensing, assays and applications. Particularly, the present invention is related to collecting a small amount of a vapor condensate sample (e.g. the exhaled breath condensate (EBC) from a subject of a volume as small as 10 fL (femto-Liter) in a single drop), preventing or significantly reducing an evaporation of the collected vapor condensate sample, analyzing the sample, analyzing the sample by mobile-phone, and performing such collection and analysis by a person without any professionals.

Devices and methods are provided for non-invasive goal oriented and personalized monitoring of substance consumption directed towards aiding reduction of substance intake by a user. Based on the substance consumption characteristics and the user's profile, the user's substance consumption profile is identified and average amount of the substance in the body at a given time is computed. A threshold corresponding to amount of substance the body can sustain is then computed based on goals set by the user and the substance consumption characteristics and the user's profile. Alerts can be generated and transmitted to the user based on pre-determined conditions to help the user achieve his set goals.

A method of treating a human subject which is effected by inhalation of gaseous nitric oxide over a period of 8 day to about 28 days is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

A method of treating a human subject which is effected by inhalation of gaseous nitric oxide, the method comprising a first treatment period comprising administering gNO by inhalation over a period of about at least 5 days, wherein the first treatment period is followed by a second treatment period comprising administering gNO by inhalation over a period of at least 3 months. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

A portable system is provided for measuring a ketone, such as an acetone, in the breath or other bodily fluid of a user. The system includes a portable measurement device that analyzes fluid samples and generates corresponding ketone measurements. The portable measurement device communicates with an application which runs on a smartphone or other mobile device of the user. The application tracks, and generates graphs of, the ketone measurements, and may include various features for facilitating the analysis of the measurements.